Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 947432, 8 pages
http://dx.doi.org/10.1155/2014/947432
Clinical Study

The Use of Humoral Responses as a Marker of CMV Burden in HIV Patients on ART Requires Consideration of T-Cell Recovery and Persistent B-Cell Activation

1School of Pathology and Laboratory Medicine, University of WA, Nedlands, WA 6009, Australia
2Microbiology and Infectious Diseases, Royal Perth Hospital, Perth, WA 6000, Australia
3Clinical Immunology and Immunogenetics, Royal Perth Hospital, Perth, WA 6000, Australia
4Immunology & Immunopathology, PathWest Laboratory Medicine, Nedlands, WA 6009, Australia
5Medicine and Pharmacology, University of WA, Nedlands, WA 6009, Australia

Received 12 September 2014; Accepted 30 October 2014; Published 23 November 2014

Academic Editor: Giuseppe Murdaca

Copyright © 2014 Samantha J. Brunt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Erice, C. Tierney, M. Hirsch et al., “Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360),” Clinical Infectious Diseases, vol. 37, no. 4, pp. 567–578, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. S. A. Spector, R. Wong, K. Hsia, M. Pilcher, and M. J. Stempien, “Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients,” The Journal of Clinical Investigation, vol. 101, no. 2, pp. 497–502, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. V. J. Goossens, P. F. Wolffs, I. H. van Loo, C. A. Bruggeman, and A. Verbon, “CMV DNA levels and CMV gB subtypes in ART-naive HAART-treated patients: a 2-year follow-up study in the Netherlands,” AIDS, vol. 23, no. 11, pp. 1425–1429, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. F. D. Verbraak, R. Boom, P. M. E. Wertheim-van Dillen, G. J. van den Horn, A. Kijlstra, and M. D. de Smet, “Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease,” British Journal of Ophthalmology, vol. 83, no. 10, pp. 1186–1189, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. S. G. Deeks, “HIV infection, inflammation, immunosenescence, and aging,” Annual Review of Medicine, vol. 62, pp. 141–155, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. C. M. Parrinello, E. Sinclair, A. L. Landay et al., “Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women,” The Journal of Infectious Diseases, vol. 205, no. 12, pp. 1788–1796, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Pawelec, E. Derhovanessian, A. Larbi, J. Strindhall, and A. Wikby, “Cytomegalovirus and human immunosenescence,” Reviews in Medical Virology, vol. 19, no. 1, pp. 47–56, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. E. T. Roberts, M. N. Haan, J. B. Dowd, and A. E. Aiello, “Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up,” American Journal of Epidemiology, vol. 172, no. 4, pp. 363–371, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Trzonkowski, J. Myśliwska, E. Szmit et al., “Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination—an impact of immunosenescence,” Vaccine, vol. 21, no. 25-26, pp. 3826–3836, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. C. A. Almeida, P. Price, and M. A. French, “Immune activation in patients infected with HIV type 1 and maintaining suppression of viral replication by highly active antiretroviral therapy,” AIDS Research and Human Retroviruses, vol. 18, no. 18, pp. 1351–1355, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. C. M. Buckner, S. Moir, J. Ho et al., “Characterization of plasmablasts in the blood of HIV-infected viremic individuals: evidence for nonspecific immune activation,” Journal of Virology, vol. 87, no. 10, pp. 5800–5811, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Moir and A. S. Fauci, “B cells in HIV infection and disease,” Nature Reviews Immunology, vol. 9, no. 4, pp. 235–245, 2009. View at Google Scholar
  13. K. Sacre, G. Carcelain, N. Cassoux et al., “Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease,” The Journal of Experimental Medicine, vol. 201, no. 12, pp. 1999–2010, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. P. W. Hunt, J. N. Martin, E. Sinclair et al., “Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy,” The Journal of Infectious Diseases, vol. 203, no. 10, pp. 1474–1483, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Moir, A. Malaspina, O. K. Pickeral et al., “Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily,” The Journal of Experimental Medicine, vol. 200, no. 7, pp. 587–599, 2004. View at Publisher · View at Google Scholar
  16. V. L. Ng, “B-lymphocytes and autoantibody profiles in HIV disease,” Clinical Reviews in Allergy & Immunology, vol. 14, no. 4, pp. 367–384, 1996. View at Google Scholar
  17. S. Moir, T.-W. Chun, and A. S. Fauci, “Pathogenic mechanisms of HIV disease,” Annual Review of Pathology: Mechanisms of Disease, vol. 6, pp. 223–248, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. D. L. Regidor, R. Detels, E. C. Breen et al., “Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation,” AIDS, vol. 25, no. 3, pp. 303–314, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Kreuzaler, M. Rauch, U. Salzer et al., “Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors,” Journal of Immunology, vol. 188, no. 1, pp. 497–503, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. F. MacKay and P. Schneider, “Cracking the BAFF code,” Nature Reviews Immunology, vol. 9, no. 7, pp. 491–502, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Strautins, M. Tschochner, I. James et al., “Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk,” Multiple Sclerosis, vol. 20, no. 3, pp. 286–294, 2014. View at Google Scholar
  22. K. Schoppel, B. Kropff, C. Schmidt, R. Vornhagen, and M. Mach, “The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies,” The Journal of Infectious Diseases, vol. 175, no. 3, pp. 533–544, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Burgess, P. Price, I. R. James et al., “Interferon-gamma responses to Candida recover slowly or remain low in immunodeficient HIV patients responding to ART,” Journal of Clinical Immunology, vol. 26, no. 2, pp. 160–167, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Gerna, G. Piccinini, E. Genini et al., “Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART,” Journal of Acquired Immune Deficiency Syndromes, vol. 28, no. 4, pp. 320–331, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. N. M. Keane, P. Price, S. Lee et al., “Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy,” HIV Medicine, vol. 5, no. 6, pp. 407–414, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Barrett, S. N. Stapleton, N. J. Fudge, and M. D. Grant, “Immune resilience in HIV-infected individuals seronegative for cytomegalovirus,” AIDS, vol. 28, no. 14, pp. 2045–2049, 2014. View at Publisher · View at Google Scholar